Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Rheumatology International

Volumn 36, Issue 8, 2016, Pages 1065-1075

  Kunwar, Sumit ^a   Dahal, Khagendra ^a   Sharma, Sharan ^a  

^a UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Anti IL 17; Brodalumab; Ixekizumab; Rheumatoid arthritis; Secukinumab

Indexed keywords

ANTIRHEUMATIC AGENT; BRODALUMAB; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; IXEKIZUMAB; SECUKINUMAB; BIOLOGICAL PRODUCT;

ANEMIA; ANXIETY DISORDER; APPENDICITIS; ARTICLE; BLEPHARITIS; BRAIN ISCHEMIA; CHOLECYSTITIS; COCHRANE LIBRARY; CYSTADENOMA; DAS28; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMBASE; FEMUR NECK FRACTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HUMAN; HYPESTHESIA; INFECTION; INTESTINE LIPODYSTROPHY; LEUKOPENIA; LUNG INSUFFICIENCY; MEDLINE; META ANALYSIS; MITRAL VALVE REGURGITATION; NECROTIZING ARTERITIS; NEUTROPENIA; NONCARDIAC CHEST PAIN; PNEUMONIA; PRIORITY JOURNAL; PROSTHESIS DISLOCATION; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SERUM SICKNESS; SKIN ABSCESS; SKIN ULCER; SPINE FRACTURE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; VESTIBULAR DISORDER; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; HUMANS; INTERLEUKIN-17; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84964301265     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-016-3480-9     Document Type: Article

References (35)

1. Martin DA, Churchill M, Flores-Suarez L et al (2013) A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 15:R164. doi:10.1186/ar4347
2. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517. doi:10.1146/annurev.immunol.021908.132710
3. Ely LK, Fischer S, Garcia KC (2009) Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 10:1245–1251. doi:10.1038/ni.1813
4. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361:888–898. doi:10.1056/NEJMra0707449
5. Furst DE, Emery P (2014) Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatol Oxf Engl 53:1560–1569. doi:10.1093/rheumatology/ket414
6. Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155–174
7. Miossec P (2000) Are T cells in rheumatoid synovium aggressors or bystanders? Curr Opin Rheumatol 12:181–185
8. Cai L, Yin JP, Starovasnik MA et al (2001) Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 16:10–21. doi:10.1006/cyto.2001.0939
9. Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol Baltim Md 1950 171:6173–6177
10. Lubberts E (2008) IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41:84–91. doi:10.1016/j.cyto.2007.09.014
11. Alzabin S, Abraham SM, Taher TE et al (2012) Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 71:1741–1748. doi:10.1136/annrheumdis-2011-201024
12. Chabaud M, Durand JM, Buchs N et al (1999) Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963–970. doi:10.1002/1529-0131(199905)42:5<963:AID-ANR15>3.0.CO;2-E
13. Ziolkowska M, Koc A, Luszczykiewicz G et al (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol Baltim Md 1950 164:2832–2838
14. Tang C, Chen S, Qian H, Huang W (2012) Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 135:112–124. doi:10.1111/j.1365-2567.2011.03522.x
15. van den Berg WB, Miossec P (2009) IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 5:549–553. doi:10.1038/nrrheum.2009.179
16. Leipe J, Grunke M, Dechant C et al (2010) Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62:2876–2885. doi:10.1002/art.27622
17. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625–639. doi:10.1002/acr.21641
18. Storage SS, Agrawal H, Furst DE (2010) Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 25:1–17. doi:10.3904/kjim.2010.25.1.1
19. Mewar D, Wilson AG (2011) Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 162:785–791. doi:10.1111/j.1476-5381.2010.01099.x
20. Gordon KB, Leonardi CL, Lebwohl M et al (2014) A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 71:1176–1182. doi:10.1016/j.jaad.2014.07.048
21. Xiong H-Z, Gu J-Y, He Z-G et al (2015) Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 8:3156–3172
22. Genovese MC, Durez P, Richards HB et al (2014) One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 41:414–421. doi:10.3899/jrheum.130637
23. Strand V, Kosinski M, Gnanasakthy A et al (2014) Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health Qual Life Outcomes 12:31. doi:10.1186/1477-7525-12-31
24. Genovese MC, Greenwald M, Cho C-S et al (2014) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol Hoboken NJ 66:1693–1704. doi:10.1002/art.38617
25. Burmester GR, Durez P, Shestakova G et al (2015) Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatol Oxf Engl. doi:10.1093/rheumatology/kev258
26. Pavelka K, Chon Y, Newmark R et al (2015) A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol 42:912–919. doi:10.3899/jrheum.141271
27. Hueber W, Patel DD, Dryja T et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72. doi:10.1126/scitranslmed.3001107
28. Genovese MC, Durez P, Richards HB et al (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863–869. doi:10.1136/annrheumdis-2012-201601
29. Genovese MC, Van den Bosch F, Roberson SA et al (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62:929–939. doi:10.1002/art.27334
30. Maringwa J, Kågedal M, Hamrén UW et al (2014) Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA). J Clin Pharmacol. doi:10.1002/jcph.406
31. Lee YH, Bae S-C, Song GG (2015) Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int. doi:10.1007/s00296-015-3291-4
32. Mease PJ, Genovese MC, Greenwald MW et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370:2295–2306. doi:10.1056/NEJMoa1315231
33. Baeten D, Baraliakos X, Braun J et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl 382:1705–1713. doi:10.1016/S0140-6736(13)61134-4
34. Koenders MI, Marijnissen RJ, Joosten LAB et al (2012) T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum 64:1762–1770. doi:10.1002/art.34352
35. van Baarsen LGM, Lebre MC, van der Coelen D et al (2014) Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther 16:426. doi:10.1186/s13075-014-0426-z